Q-omics provides the consensus-scored STRA8 profile across patient tissues and cancer cell-line models. STRA8 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, STRA8 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, STRA8 RNA expression shows 9,838 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where STRA8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STRA8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STRA8 survival associations across molecular data types. STRA8 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STRA8 RNA expression–survival associations across cancer types. High STRA8 expression shows unfavorable associations in BLCA, DLBC and COAD, but favorable associations in OV, KIRP and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for STRA8 RNA expression.
This table summarizes STRA8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for STRA8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STRA8 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, KIRP, LIHC and LUSC. The KIRC box plot shows higher STRA8 RNA expression in tumor versus normal tissue (log2 FC = +1.742, t-test p < 0.001).
This table shows molecular features associated with STRA8 in patient tissues and cancer cell lines. In patient samples, STRA8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, STRA8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
